maalox 40 mg/35 mg/ml suspensija iekšķīgai lietošanai
opella healthcare france s.a.s., france - aluminii hydroxidum, magnija hydroxidum - suspensija iekšķīgai lietošanai - 40 mg/35 mg/ml
maalox 460 mg/400 mg/4,3 ml suspensija iekšķīgai lietošanai
opella healthcare france s.a.s., france - aluminii hydroxidum, magnija hydroxidum - suspensija iekšķīgai lietošanai - 460 mg/400 mg/4,3 ml
maalox 400 mg/400 mg košļājamās tabletes (nesatur cukuru)
opella healthcare france s.a.s., france - aluminii hydroxidum, magnija hydroxidum - košļājamā tablete - 400 mg/400 mg
onkotrone 20 mg/10 ml koncentrāts infūziju šķīduma pagatavošanai
baxter latvia, sia, latvia - mitoksantrona hidrohlorīds - koncentrāts infūziju šķīduma pagatavošanai - 2 mg/ml
linola urea 120 mg/g krēms
dr. august wolff gmbh & co. kg arzneimittel, germany - urīnviela - krēms - 120 mg/g
onkotrone 10 mg/5 ml koncentrāts infūziju šķīduma pagatavošanai
baxter latvia, sia, latvia - mitoksantrona hidrohlorīds - koncentrāts infūziju šķīduma pagatavošanai - 2 mg/ml
pelgraz
accord healthcare s.l.u. - pegfilgrastim - neitropēnija - imunitātes stimulatori, - ilguma samazināšanās neutropenia un biežums pacientiem drudža neutropenia ārstēti ar citotoksiskas ķīmijterapijas ļaundabīgo audzēju (izņemot myeloid hroniskas leikēmijas un myelodysplastic sindromi).
pelmeg
mundipharma corporation (ireland) limited - pegfilgrastim - neitropēnija - imunitātes stimulatori, - lai samazinātu ilgums neutropenia un sastopamība febrila neutropenia sakarā ar ķīmijterapiju.
nyvepria
pfizer europe ma eeig - pegfilgrastim - neitropēnija - imunitātes stimulatori, - ilguma samazināšanās neutropenia un saslimstība ar pieaugušiem pacientiem drudža neutropenia ārstēti ar citotoksiskas ķīmijterapijas ļaundabīgo audzēju (izņemot myeloid hroniskas leikēmijas un myelodysplastic sindromi).
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doksorubicīns - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.